Novocure Ltd Stock
Price
Target price
€15.48
€15.48
-0.260%
-0.04
-0.260%
-
05.07.24 / Tradegate
WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Novocure Ltd Stock
Novocure Ltd shows a slight decrease today, losing -€0.040 (-0.260%) compared to yesterday.
For the coming years our community has positive and negative things to say abot the Novocure Ltd stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -0.260% | -5.070% | -25.512% | -59.662% | 9.527% | -89.926% | - |
| Ironwood Pharmaceuticals | -2.610% | 0.877% | -7.258% | -39.153% | -43.627% | -46.262% | - |
| Iovance Biotherapeutics Inc. | -1.970% | -8.984% | -8.371% | 4.578% | -12.807% | -69.512% | - |
| Fibrogen Inc. | -0.600% | -29.899% | -51.069% | -73.858% | -21.420% | -97.009% | -98.306% |
News
Novocure to Report Second Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the